Cardiovascular diseases are leading cause of morbidity and mortality globally. Biomarkers are generally used as an indicator forparticular diseases such as rheumatic and congenital heart diseases and cardiac arrhythmia. Cardiac biomarkers are measurable and quantifiable biological parameters. These are specifically used to check the presence or severity of cardiovascular diseases. Cardiac biomarkers are the substances that are released into blood when heart is damaged. These biomarkers are also used for diagnosing and monitoring diseases such as coronary syndrome or cardiac ischemia. The symptoms of these diseases includes chest pain, shortness of breath and nausea that ultimately leads to heart attack or angina. Cardiac biomarker tests helps to detect presence of coronary syndrome and cardiac ischemia to evaluate its severity and diagnosis.
The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state and used for diagnostic and prognostic purposes associated with heart. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. Cardiac biomarkers market has witnessed a greater demand over the past five to six years. 

Market Analysis and Insights: Global Cardiac Biomarkers Market
The global Cardiac Biomarkers market size is projected to reach US$ 1315.7 million by 2027, from US$ 704.2 million in 2020, at a CAGR of 9.2% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cardiac Biomarkers market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cardiac Biomarkers market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cardiac Biomarkers market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cardiac Biomarkers market.

Global Cardiac Biomarkers Scope and Market Size
Cardiac Biomarkers market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cardiac Biomarkers market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Troponin
CK-MB
Natriuretic Peptides - BNP and NT-proBNP
Myoglobin
Others

Segment by Application
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Abbott
Abbott
F. Hoffmann-La Roche
Advanced ImmunoChemical
AgPlus Diagnostics
BG Medicine
BioLegend
bioMérieux
Bio-Rad Laboratories
BODITECH MED